Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adiponectin and Leptin Signaling Pathway
- Molecular classification
- Protein hormone, Adipokine, Receptor ligand
01
Overview
Adiponectin and leptin are two prominent adipokines (hormones secreted by adipose tissue) that play antagonistic roles in various physiological and pathological processes. These molecules are involved in metabolic regulation, cardiovascular function, and cancer development. Their imbalance in conditions like obesity contributes to various pathological states, making them attractive targets for therapeutic intervention in cancer, cardiovascular diseases, and neurodegenerative disorders.
- Other names
- Adipocytokine modulation (adiponectin/leptin)Adiponectin/Leptin Axis
02
Mechanism of action
Therapeutic interventions targeting the adiponectin/leptin axis aim to modulate the balance and signaling pathways of these hormones. This includes strategies to increase the adiponectin/leptin ratio, reduce leptin levels, inhibit leptin-induced downstream signaling pathways (e.g., JAK2/STAT3, PI3K/Akt, ERK), enhance adiponectin signaling (e.g., via AdipoR1/AdipoR2 leading to AMPK and PPARα activation), and specifically enhance leptin signaling in the brain for neurodegenerative contexts.
03
Biological functions
Metabolic regulation, including energy homeostasis, lipid metabolism, and insulin sensitivityModulation of cell proliferation, migration, and invasionRegulation of apoptosisControl of angiogenesisRegulation of synaptic plasticity
04
Disease associations
Cancer (leptin promotes cancer cell proliferation, migration, and invasion; adiponectin has anti-cancer properties)Cardiovascular Disorders (obesity-associated hyperleptinemia and hypoadiponectinemia are biomarkers for predicting cardiovascular outcomes; adiponectin is generally cardioprotective; leptin's role is complex)Neurodegenerative Diseases (e.g., Alzheimer's disease, where low adiponectin levels and central leptin resistance contribute to brain pathology; leptin treatment improves memory performance)Obesity and Metabolic Disorders (leptin levels directly associated with adipose tissue mass; adiponectin levels downregulated in obesity; the adiponectin/leptin ratio is altered)
05
Biomarkers
Leptin-to-adiponectin ratio (for cancer outcomes and cardiovascular risk)Obesity-associated hyperleptinemiaHypoadiponectinemia
Beyond the preview
Go deeper on Adiponectin and Leptin Signaling Pathway.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adiponectin and Leptin Signaling Pathway.